Skip to main content
SpringerLink
Log in

Drug Safety Information Through the Internet

The Experience of an Italian Website

  • Original Research Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Background: The Internet may play a crucial role in the prompt provision of updated drug safety information. Nevertheless, limited knowledge of the English language among healthcare professionals or suboptimal search skills constitute barriers to widespread and appropriate use of the Internet for this purpose in Italy. In order to provide accurate information on drug safety and to promote the reporting of adverse drug reactions, in 1999 the clinical section of the Italian Society of Pharmacology created the website www.farmacovigilanza.org, financially supported by a non-profit foundation. The website promptly and independently provides news published in the international literature on drug safety, translated into Italian. The site also contains specific sections dedicated to adverse reactions to herbal products and cosmetic preparations.

Objectives: The aim of this paper was to describe the number and characteristics of users and the most intensively visited sections of the website. Furthermore, in September 2006, 300 registered users who had accessed a registered users area aimed specifically at health professionals more than 20 times in the preceding 12 months received a ten-item multiple choice questionnaire via e-mail, to assess satisfaction with the accuracy and promptness of information provided, text comprehension and other information sources for drug-related issues. We hereby describe the results of the survey, after careful analysis of the questionnaires.

Results: Up until July 2007, the site had over 600 000 direct accesses and 9760 healthcare professionals registered to use the site. A total of 108 responses to the e-mailed questionnaire were received (response rate = 36%), of which 103 were analysed; five were excluded due to missing information. Overall, the majority of responders judged the information on the site as objective and understandable. More than 85% of participants declared that the site has influenced their opinion and attitudes toward the safety of medicines. In particular, responders said that they pay more attention to drug interactions and to the safety profile of newly marketed drugs, and spend more time on communicating the risks of drugs used by their patients. Specifically, responders stated that they pay more attention to drug interactions (87.7%), newly marketed drugs (68.5%), herbal remedies (56.2%), drugs in patients at increased risk (42.5%), drugs in pregnant women (42.5%) and cosmetics (13.7%).

Conclusions: The website www.farmacovigilanza.org appears to be an effective tool that provides users of the site with independent, relevant and reliable safety information. It was found to influence (and possibly improve) the quality of prescribing of a large proportion of the general practitioners who responded to our questionnaire, and our results indicate a high appreciation of the information found on the website. Moreover, the survey disclosed that there is a substantial need for such information in the national language by healthcare professionals. We think that our approach can serve as a model for similar initiatives in countries elsewhere in the world.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2
Table III

Similar content being viewed by others

|References

  1. Johansson K, Olsson S, Hellman B, et al. An analysis of Vigimed, a global e-mail system for the exchange of pharmacovigilance information. Drug Saf 2007; 30: 883–9

    Article  PubMed  Google Scholar 

  2. Winker MA, Flanagin A, Chi-Lum B, et al. Guidelines for medical and health information sites on the internet: principles governing AMA web sites. American Medical Association. JAMA 2000; 283(12): 1600–6

    Article  PubMed  CAS  Google Scholar 

  3. Council for International Organizations of Medical Sciences (CIOMS). Reporting adverse drug reactions: definition of terms and criteria for their use. Geneva: CIOMS, 1999

    Google Scholar 

  4. WHO. WHO World Health Statistics WHOSIS (WHO Statistical Information System) 2007 [online]. Available from URL: http://www.who.int/whosis/indicators/2007HumanResourcesForHealth/en/index.html. [Accessed 2008 Jun 13]

  5. Tatsioni A, Gerasi E, Charitidou E, et al. Important drug safety information on the internet: assessing its accuracy and reliability. Drug Saf 2003; 26: 519–27

    Article  PubMed  Google Scholar 

  6. Eysenbach G, Powell J, Kuss O, et al. Empirical studies assessing the quality of health information for consumers on the world wide web: a systematic review. JAMA 2002; 287: 2691–700

    Article  PubMed  Google Scholar 

  7. Martin-Facklam M, Kostrzewa M, Martin P, et al. Quality of drug information on the World Wide Web and strategies to improve pages with poor information quality: an intervention study on pages about sildenafil. Br J Clin Pharmacol 2004; 57: 80–5

    Article  PubMed  Google Scholar 

  8. Waack KE, Ernst ME, Graber MA. Informational content of official pharmaceutical industry web sites about treatments for erectile dysfunction. Ann Pharmacother 2004; 38: 2029–34

    Article  PubMed  Google Scholar 

  9. Clauson KA, Polen HH, Boulos MN, et al. Scope, completeness, and accuracy of drug information in Wikipedia. Ann Pharmacother 2008; 42: 1814–21

    Article  PubMed  Google Scholar 

  10. Thompson AE, Graydon SL. Patient-oriented methotrexate information sites on the internet: a review of completeness, accuracy, format, reliability, credibility, and readability. J Rheumatol. Epub 2008 Nov 1

  11. Beaton C, Codd RJ, Holland PA, et al. Evaluation of the quality and accuracy of information regarding aromatase inhibitors available on the internet. Breast J 2008; 14: 366–8

    Article  PubMed  Google Scholar 

  12. Waller PC, Evans SJ, Beard K. Drug safety and regulation. BMJ 2005; 331: 4–5

    Article  PubMed  Google Scholar 

  13. Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet 2004; 364: 1995–6

    Article  PubMed  Google Scholar 

  14. Vioxx: lessons for Health Canada and the FDA [editorial]. CMAJ 2005; 172: 5

    Article  Google Scholar 

  15. Topol EJ. Failing the public health: rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351:1707–9

    Article  PubMed  CAS  Google Scholar 

  16. Lenzer J. FDA is incapable of protecting US “against another Vioxx” [news]. BMJ 2004; 329: 1253

    Article  PubMed  Google Scholar 

  17. Drazen JM. COX-2 inhibitors: a lesson in unexpected problems. N Engl J Med 2005; 352: 1131–2

    Article  PubMed  CAS  Google Scholar 

  18. Horton R. Safety concerns at the FDA. Lancet 2005; 365: 727–8

    Google Scholar 

  19. Relevant health information for empowered citizens. Joint Declaration of HAI Europe. ISDB, AIM, BEUC, Medicines in Europe Forum, Bruxelles, 3 October 2006 [online]. Available from URL: http://intergroup.epha.org/IMG/pdf/ExecutiveSumFINAL2909.pdf [Accessed 2009 Mar 26]

Download references

Acknowledgements

The authors would like to thank Dr Laura Iris Ferro for supporting the website, and all the colleagues who have contributed to its contents. A special thanks goes to Ms Antonina Donato for reviewing the English. No sources of funding were used in the preparation of this study. The authors have no conflicts of interest to declare that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro Neurolesi “Bonino-Pulejo”, Via Palermo, C.da Casazza, 98124, Messina, Italy

    Giovanni Polimeni & Achille P. Caputi

  2. Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Messina, Italy

    Alessandra Russo, Maria Antonietta Catania, Andrea Aiello, Alessandro Oteri, Gianluca Trifirò, Gioacchino Calapai & Achille P. Caputi

  3. Department of Experimental Pharmacology, University of Naples Federico II, Naples, Italy

    Lidia Sautebin

  4. Fondazione Gianfranco Ferro, Milan, Italy

    Massimo Iacobelli

Authors
  1. Giovanni Polimeni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandra Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Antonietta Catania
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea Aiello
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alessandro Oteri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gianluca Trifirò
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gioacchino Calapai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lidia Sautebin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Massimo Iacobelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Achille P. Caputi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Polimeni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Polimeni, G., Russo, A., Catania, M.A. et al. Drug Safety Information Through the Internet. Drug-Safety 32, 245–253 (2009). https://doi.org/10.2165/00002018-200932030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200932030-00007

Keywords

Search

Navigation